Real-time RT-PCR Assay for Detection and Characterization of North American Lineage of A/H7 Influenza Viruses

This technology includes an updated North American Lineage H7 (N.A H7) real-time RT-PCR assay is designed for specific detection and characterization of North American lineage of A/H7 influenza viruses. Since 1995, poultry infection with N.A lineage influenza A/H7 viruses has been greatly increasing. The outbreaks of N.A A/H7 viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 viruses have been confirmed following exposure to infected poultry.

Combination Dosing Regimens for the Prevention of HIV

This technology includes combinations of currently approved antiretrovirals (ARVs) which could allow for simpler dosing regimens that improve adherence to HIV prevention strategies. Event-Driven PrEP (ED-PrEP) with 2 oral doses of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) taken 2-24 hours before sex, a 3rd dose 24 hours after sex, and a 4th dose 48 hours after sex (2+1+1) is considered as a PrEP option by the World Health Organization for men who have sex with men (MSM). Recommended post-exposure prophylaxis (PEP) regimens require 28 days of daily oral dosing.

Cell Line for Adult T-cell Leukemia with Stable Co-expression of CD4 and CD8 for the Development of Therapeutics

This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products.

Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools

This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.

Sodium Nitrite as a Repurposed Pharmaceutical Agent Wins LES Deals of Distinction Award

LES logo

The 2009 award winner for this category is a group of licensing agreements for the development of sodium nitrite as a repurposed pharmaceutical agent potentially effective against a number of serious medical conditions. The National Institutes of Health (NIH), supported by four university collaborators, was able complete exclusive license agreements with Hope Pharmaceuticals (for infused delivery) and Aires Pharmaceuticals (for inhaled delivery) to develop new treatments for conditions not well-managed by existing therapies.

Zinbryta® for Treatment of Relapsing Multiple Sclerosis

LES logo

The 2017 Deals of Distinction™ Award was presented to National Institutes of Health, (NIH) along with its corporate partners, AbbVie and Biogen, for a license agreement related to the development and launch of Zinbryta® for treatment of relapsing multiple sclerosis (MS)   The award, one of the most prestigious for technology transfer, was given to NIH and its partners at the Licensing Executives Society Annual Meeting in Chicago, Illinois.

NIH Wins Licensing Executive Society Deals of Distinction Award for WHO C-TAP Partnership

LES logo

The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended the LES award ceremony to accept the award on NIH’s behalf. Continue reading to learn about this award-winning license agreement from Steve himself.

Dr. Ken Jacobson Wins E.B. Hershberg Award

ACS Chemistry for Life

The American Chemical Society (ACS) has awarded Kenneth Jacobson the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Jacobson is a Senior Investigator at the National Institute for Diabetes and Digestive and Kidney Diseases.

Jacobson was selected for this award for his original and high-impact research in structure-based medicinal chemistry, including the discovery of G-protein receptor modulators in clinical trials.

Changing Lives in PASLI/APDS Patients, Disease Discovery and Treatment.

FLC logo

THE PROBLEM: APDS (activated PI3 kinase delta syndrome) — also known as PASLI (p110 delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) disease — is a rare disorder that severely impairs the immune system’s ability to fight bacterial and viral infections, making patients susceptible to severe and recurrent infections, lymphoma, autoimmune diseases and other health issues. This disease is estimated to affect up to two people per million, and it can only be cured via bone marrow transplant.

Subscribe to Therapeutics